Robert F. Spiera

Dec 18, 2023 | healio.com | Erich Martin |Shenaz Bagha |Robert F. Spiera

You've successfully added Rheumatology: Practice Management to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse event associated with sarilumab was neutropenia.

Dec 18, 2023 | healio.com | Erich Martin |Shenaz Bagha |Robert F. Spiera

You've successfully added Primary Care: Rheumatology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse event associated with sarilumab was neutropenia.

Oct 11, 2023 | rheumnow.com | Robert F. Spiera

TRANSCRIPT:Hi, this is Robert Spiro from the Hospital for Special Surgery in New York. I'll be speaking today about a question, which is whether IL-6 inhibiting therapies should be used early or late in the course of treating patients with polymyalgia rheumatica. It's exciting to be able to have this conversation because it's only in the past year that we have an approved non-corticosteroid therapy for polymyalgia rheumatica that's been shown to be effective in a well done clinical trial.